-
1
-
-
0028057250
-
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
-
M.E. Reff, K. Carner, K.S. Chambers, P.C. Chinn, J.E. Leonard, and R. Raab Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435 445
-
(1994)
Blood
, vol.83
, pp. 435-445
-
-
Reff, M.E.1
Carner, K.2
Chambers, K.S.3
Chinn, P.C.4
Leonard, J.E.5
Raab, R.6
-
2
-
-
0034777814
-
CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells
-
N. Selenko, O. Maidic, S. Draxier, A. Berer, U. Jäger, and W. Knapp CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells Leukemia 15 2001 1619 1626
-
(2001)
Leukemia
, vol.15
, pp. 1619-1626
-
-
Selenko, N.1
Maidic, O.2
Draxier, S.3
Berer, A.4
Jäger, U.5
Knapp, W.6
-
3
-
-
0034671315
-
Anti-CD20- and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways
-
S. Mathas, A. Rickers, K. Bommert, B. Dorken, and M.Y. Mapara Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways Cancer Res 60 2000 7170 7176
-
(2000)
Cancer Res
, vol.60
, pp. 7170-7176
-
-
Mathas, S.1
Rickers, A.2
Bommert, K.3
Dorken, B.4
Mapara, M.Y.5
-
4
-
-
0034104375
-
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
-
D. Shan, J.A. Ledbetter, and O.W. Press Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells Cancer Immunol Immunother 48 2000 673 683
-
(2000)
Cancer Immunol Immunother
, vol.48
, pp. 673-683
-
-
Shan, D.1
Ledbetter, J.A.2
Press, O.W.3
-
5
-
-
17144455839
-
IDEC-C2B8: Result of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
-
D.G. Maloney, A.J. Grillo-Lopez, D.J. Bodkin, C.A. White, T.M. Liles, and I. Royston IDEC-C2B8: result of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma J Clin Oncol 15 1997 3266 3274
-
(1997)
J Clin Oncol
, vol.15
, pp. 3266-3274
-
-
Maloney, D.G.1
Grillo-Lopez, A.J.2
Bodkin, D.J.3
White, C.A.4
Liles, T.M.5
Royston, I.6
-
6
-
-
0345337254
-
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
-
P. McLaughlin, A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, and M.E. Williams Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 1998 2825 2833
-
(1998)
J Clin Oncol
, vol.16
, pp. 2825-2833
-
-
McLaughlin, P.1
Grillo-Lopez, A.J.2
Link, B.K.3
Levy, R.4
Czuczman, M.S.5
Williams, M.E.6
-
7
-
-
0033968522
-
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
-
J.M. Foran, A.Z. Rohatiner, D. Cunningham, R.A. Popescu, P. Solal-Celigny, and M. Ghielmini European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma J Clin Oncol 18 2000 317 324
-
(2000)
J Clin Oncol
, vol.18
, pp. 317-324
-
-
Foran, J.M.1
Rohatiner, A.Z.2
Cunningham, D.3
Popescu, R.A.4
Solal-Celigny, P.5
Ghielmini, M.6
-
8
-
-
0032791210
-
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
-
L.D. Piro, C.A. White, A.J. Grillo-Lopez, N. Janakiraman, A. Saven, and T.M. Beck Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma Ann Oncol 10 1999 655 661
-
(1999)
Ann Oncol
, vol.10
, pp. 655-661
-
-
Piro, L.D.1
White, C.A.2
Grillo-Lopez, A.J.3
Janakiraman, N.4
Saven, A.5
Beck, T.M.6
-
9
-
-
7844225540
-
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
-
N.L. Berinstein, A.J. Grillo-Lopez, C.A. White, I. Bence-Bruckler, D. Maloney, and M. Czuczman Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma Ann Oncol 9 1998 995 1001
-
(1998)
Ann Oncol
, vol.9
, pp. 995-1001
-
-
Berinstein, N.L.1
Grillo-Lopez, A.J.2
White, C.A.3
Bence-Bruckler, I.4
Maloney, D.5
Czuczman, M.6
-
10
-
-
0032530342
-
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
-
B. Coiffier, C. Haioun, N. Ketterer, A. Engert, H. Tilly, and D. Ma Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 92 1998 1927 1932
-
(1998)
Blood
, vol.92
, pp. 1927-1932
-
-
Coiffier, B.1
Haioun, C.2
Ketterer, N.3
Engert, A.4
Tilly, H.5
Ma, D.6
-
11
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma
-
B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, and R. Bouabdallah CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma N Engl J Med 346 2002 235 242
-
(2002)
N Engl J Med
, vol.346
, pp. 235-242
-
-
Coiffier, B.1
Lepage, E.2
Briere, J.3
Herbrecht, R.4
Tilly, H.5
Bouabdallah, R.6
-
12
-
-
0037698992
-
Rituximab plus CHOP (R-CHOP) overcomes bcl-2 - Associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
-
N. Mounier, J. Briere, C. Gisselbrecht, J.F. Emile, P. Lederlin, and C. Sebban Rituximab plus CHOP (R-CHOP) overcomes bcl-2 - associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood 101 2003 4279 4284
-
(2003)
Blood
, vol.101
, pp. 4279-4284
-
-
Mounier, N.1
Briere, J.2
Gisselbrecht, C.3
Emile, J.F.4
Lederlin, P.5
Sebban, C.6
-
13
-
-
4344660758
-
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma
-
P.L. Zinzani, A. Pulsoni, A. Perrotti, S. Soverini, F. Zaja, and A. De Renzo Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma J Clin Oncol 22 2004 2654 2661
-
(2004)
J Clin Oncol
, vol.22
, pp. 2654-2661
-
-
Zinzani, P.L.1
Pulsoni, A.2
Perrotti, A.3
Soverini, S.4
Zaja, F.5
De Renzo, A.6
-
14
-
-
13244270361
-
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
-
R. Marcus, K. Imrie, A. Belch, D. Cunningham, E. Flores, and J. Catalano CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma Blood 105 2005 1417 1423
-
(2005)
Blood
, vol.105
, pp. 1417-1423
-
-
Marcus, R.1
Imrie, K.2
Belch, A.3
Cunningham, D.4
Flores, E.5
Catalano, J.6
-
15
-
-
9444247655
-
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: A prospective, multicenter phase II study
-
W. Brugger, J. Hirsch, F. Grunebach, R. Repp, P. Brossart, and W. Vogel Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study Ann Oncol 15 2004 1691 1698
-
(2004)
Ann Oncol
, vol.15
, pp. 1691-1698
-
-
Brugger, W.1
Hirsch, J.2
Grunebach, F.3
Repp, R.4
Brossart, P.5
Vogel, W.6
-
16
-
-
13244288836
-
Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up
-
M.S. Czuczman, R. Weaver, B. Alkuzweny, J. Berlfein, and A.J. Grillo-Lopez Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up J Clin Oncol 22 2004 4711 4716
-
(2004)
J Clin Oncol
, vol.22
, pp. 4711-4716
-
-
Czuczman, M.S.1
Weaver, R.2
Alkuzweny, B.3
Berlfein, J.4
Grillo-Lopez, A.J.5
-
17
-
-
14944343819
-
Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: A phase II trial of the minnie pearl cancer research network
-
J.D. Hainsworth, S. Litchy, L.H. Morrissey, M.B. Andrews, M. Grimaldi, and M. McCarty Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network J Clin Oncol 23 2005 1500 1506
-
(2005)
J Clin Oncol
, vol.23
, pp. 1500-1506
-
-
Hainsworth, J.D.1
Litchy, S.2
Morrissey, L.H.3
Andrews, M.B.4
Grimaldi, M.5
McCarty, M.6
-
18
-
-
14544274608
-
Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders
-
L.N. Gordan, W.B. Grow, A. Pusateri, V. Douglas, N.P. Mendenhall, and J.W. Lynch Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders J Clin Oncol 23 2005 1096 1102
-
(2005)
J Clin Oncol
, vol.23
, pp. 1096-1102
-
-
Gordan, L.N.1
Grow, W.B.2
Pusateri, A.3
Douglas, V.4
Mendenhall, N.P.5
Lynch, J.W.6
-
19
-
-
20044362555
-
Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group
-
T.E. Witzig, A.M. Vukov, T.M. Habermann, S. Geyer, P.J. Kurtin, and W.R. Friedenberg Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group J Clin Oncol 23 2005 1103 1108
-
(2005)
J Clin Oncol
, vol.23
, pp. 1103-1108
-
-
Witzig, T.E.1
Vukov, A.M.2
Habermann, T.M.3
Geyer, S.4
Kurtin, P.J.5
Friedenberg, W.R.6
-
20
-
-
0034999619
-
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
-
S.P. Treon, C. Mitsiades, N. Mitsiades, G. Young, D. Doss, and R. Schlossman Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies J Immunother 24 2001 263 271
-
(2001)
J Immunother
, vol.24
, pp. 263-271
-
-
Treon, S.P.1
Mitsiades, C.2
Mitsiades, N.3
Young, G.4
Doss, D.5
Schlossman, R.6
-
21
-
-
0035760902
-
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59
-
J. Golay, M. Lazzari, V. Faccinetti, S. Bernasconi, G. Borleri, and T. Barbui CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 Blood 98 2001 3383 3389
-
(2001)
Blood
, vol.98
, pp. 3383-3389
-
-
Golay, J.1
Lazzari, M.2
Faccinetti, V.3
Bernasconi, S.4
Borleri, G.5
Barbui, T.6
-
22
-
-
0035469885
-
Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
-
W.K. Weng, and R. Levy Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma Blood 98 2001 1352 1357
-
(2001)
Blood
, vol.98
, pp. 1352-1357
-
-
Weng, W.K.1
Levy, R.2
-
23
-
-
0034660092
-
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
-
J. Golay, L. Zaffaroni, T. Vaccari, M. Lazzari, G.M. Borleri, and S. Bernasconi Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood 95 2000 3900 3908
-
(2000)
Blood
, vol.95
, pp. 3900-3908
-
-
Golay, J.1
Zaffaroni, L.2
Vaccari, T.3
Lazzari, M.4
Borleri, G.M.5
Bernasconi, S.6
-
24
-
-
0037306893
-
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
-
O. Manches, G. Lui, L. Chaperot, R. Gressin, J.P. Molens, and M.C. Jacob In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas Blood 101 2003 949 954
-
(2003)
Blood
, vol.101
, pp. 949-954
-
-
Manches, O.1
Lui, G.2
Chaperot, L.3
Gressin, R.4
Molens, J.P.5
Jacob, M.C.6
-
25
-
-
0036123109
-
CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy
-
W.T. Massengale, E. McBurney, and J. Gurtler CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy J Am Acad Dermatol 46 2002 441 443
-
(2002)
J Am Acad Dermatol
, vol.46
, pp. 441-443
-
-
Massengale, W.T.1
McBurney, E.2
Gurtler, J.3
-
26
-
-
0033055251
-
Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
-
T.A. Davis, D.K. Czerwinski, and R. Levy Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression Clin Cancer Res 5 1999 611 615
-
(1999)
Clin Cancer Res
, vol.5
, pp. 611-615
-
-
Davis, T.A.1
Czerwinski, D.K.2
Levy, R.3
-
27
-
-
0032406790
-
CD20-negative relapse in B-cell lymphoma after treatment with rituximab
-
T. Kinoshita, H. Nagai, T. Murate, and H. Saito CD20-negative relapse in B-cell lymphoma after treatment with rituximab J Clin Oncol 16 1998 3916
-
(1998)
J Clin Oncol
, vol.16
, pp. 3916
-
-
Kinoshita, T.1
Nagai, H.2
Murate, T.3
Saito, H.4
-
28
-
-
0032821561
-
Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab
-
K. Schmitz, W. Brugger, B. Weiss, E. Kaiserling, and L. Kanz Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab Br J Haematol 106 1999 571 572
-
(1999)
Br J Haematol
, vol.106
, pp. 571-572
-
-
Schmitz, K.1
Brugger, W.2
Weiss, B.3
Kaiserling, E.4
Kanz, L.5
-
29
-
-
0036023451
-
Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells
-
R.B. Michel, and M.J. Mattes Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells Clin Cancer Res 8 2002 2701 2713
-
(2002)
Clin Cancer Res
, vol.8
, pp. 2701-2713
-
-
Michel, R.B.1
Mattes, M.J.2
-
30
-
-
0028263670
-
Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells - An immunofluorescence and immunoelectron microscopy study
-
S. Pulczynski, A.M. Boesen, and O.M. Jensen Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells - an immunofluorescence and immunoelectron microscopy study Leuk Res 18 1994 541 552
-
(1994)
Leuk Res
, vol.18
, pp. 541-552
-
-
Pulczynski, S.1
Boesen, A.M.2
Jensen, O.M.3
-
31
-
-
0242492546
-
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
-
I. Jilani, S. O'Brien, T. Manshuri, D.A. Thomas, V.A. Thomazy, and M. Imam Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia Blood 102 2003 3514 3520
-
(2003)
Blood
, vol.102
, pp. 3514-3520
-
-
Jilani, I.1
O'Brien, S.2
Manshuri, T.3
Thomas, D.A.4
Thomazy, V.A.5
Imam, M.6
|